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Abstract: This review article gathers evidence on the potential relationship between dietary intake of ?3 polyunsaturated 
fatty acids (?3 PUFAs) and mental function. Several pieces of evidence that ?3 PUFAs influence affective and cognitive 
function are presented. 
Although published data and results available in the field remain limited and sometimes ambiguous, they have shed a new 
light on the role of proper diet in general, ?3 PUFAs in particular, in many mental disorders and dysfunctions, including 
depression and cognitive decline in aging. The analysis of the influence of fatty acids on human health allows us to formu-
late a new, more holistic approach to both prevention and treatment of psychological disorders and dysfunctions. What is 
more, it appears that ?3 PUFAs have a beneficial influence on mental function in healthy people as well. 
The currently available data concerning the influence of fatty acids on behaviour and mental function are still insufficient 
and suffer so far from lack of standard determination of background, intermediairy and endpoint omega-6/3 ratios  
in plasma lipids of patients involved in both epidemiological and intervention studies. There is a great need for further  
refined trials in the field. 
Keywords: Diets, food, nutrients, nutraceuticals, depression, anxiety, type A behaviour. 
INTRODUCTION 
 It is known that brain function is highly sensitive to die-
tary nutrients. One of the probably best known examples is 
caffeine, which is contained in tea, coffee, chocolate etc. 
Caffeine is a stimulant that improves mental alertness and 
performance. Many other dietary elements – from vitamins 
to macro-elements – influence brain biochemistry and func-
tion. Some silently while others have been reported to have 
behavioural and functional effects. As the study of brain nu-
trition and, in particular, its impact on brain function and 
behaviour is relatively new, it is not surprising that gaps re-
main to be filled in our knowledge of the biochemical, 
physiological, psychological and behavioural aspects of the 
effects of diet on brain function. However, accurate and rele-
vant data are available from where functional effects appear 
obvious though underlying mechanisms are still poorly un-
derstood. The aim of this article is to review and discuss the 
effects of essential nutrients (particularly ?3 PUFAs) on 
psychological function and mental health.  
NUTRIENTS AND BRAIN FUNCTION  
 Polyunsaturated fatty acids (PUFAs) constitute key struc-
tural components of phospholipid membranes in body  
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tissues. They are highly concentrated in the central nervous 
system (CNS) and human brain [1]. They play a role in 
nervous system activity, neuroplasticity of nerve membranes 
[2], synaptogenesis [3], synaptic transmission [4] and neuro-
transmitter uptake. Most neurotransmitters, i.e. catechola-
mines, acetylcholines and serotonin, also affect the function 
of the cardiovascular system, in addition to their effects on 
neuropsychiatric dysfunctions [5-8]. The synthesis of neuro-
transmitters has been shown to also depend on a number of 
other essential nutrients such as tryptophan, tyrosine, argin-
ine. and choline [6, 7]. There is evidence that ?3 fatty acids 
and other nutrients can affect cognitive function, mood, type-
A behaviour, and depression [6-14]. In this respect, excess 
intakes of linoleic acid (C18: 2?6), saturated fat and trans-
unsaturated fats, refined carbohydrates, are pro-inflammatory 
leading to increased plasma levels of activating protein-1 
(AP-1) and early response growth protein-1 (ERGP-1), 
which are transcription factors for pro-inflammatory cytoki-
nes. These latter cytokines appear to be positively associated 
with depression and type-A behaviour which are also risk 
factors for heart disease. On the other hand, ?3 fatty acids, 
monounsaturated fatty acids, antioxidant vitamins, flavon-
oids, coenzyme Q10, potassium, magnesium, calcium and 
moderate alcohol seem to have beneficial effects on brain 
and heart function as well as on mental function (Table 1).  
 The brain is responsible for approximately one fifth  
of the basal metabolism, which is fuelled by glucose and  
oxygen. Protein and lipids material are essential to the 
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growth and regeneration of myelin sheaths and axis cylinders 
as well as for enzyme systems needed for cellular metabo-
lism and neuroprotection. Vitamins, minerals and electro-
lytes, ?3 fatty acids and coenzyme Q10 in the neurons may 
influence the excitability of nerve centres. These vitamins, 
minerals, antioxidants, flavonoids and ?3 fatty acids should 
be adequately available as these nutrients can affect glucose 
metabolism, which is necessary for neuronal functions.  
Deficiencies in B vitamins, including folic acid, may be con-
nected with psychological disorders. Epidemiological studies 
indicate that consumption of diets rich in antioxidants and 
anti-inflammatory compounds such as those found in fruits 
and vegetables (i.e. polyphenols), may lower the risk of de-
veloping age-related, neurodegenerative diseases, such as 
Alzheimer’s or Parkinsons’s diseases [15]. 
POLYUNSATURATED FATTY ACIDS (PUFAS) 
 Omega-6/3 PUFAs are essential to mammals, including 
humans; they cannot be synthesized in vivo and have to be 
obtained from the diet. PUFAs are composed of a hydrocar-
bon chain of variable lengths with a methyl group at one end 
(omega end), a carboxyl group at the opposite end, and sev-
eral double bonds in between. The position of the first dou-
ble bond differentiates ?3 fatty acids (i.e. C18:3?3 or ALA 
or alpha-linolenic acid) and ?6 fatty acids (i.e. C18:2?6 or 
LA or linoleic acid) [10]. ?3 PUFAs have their first double 
bond at the third carbon, while ?6 PUFAs at the sixth carbon 
from the omega end. In the wild, ALA, often referred to as 
short chain ?3 PUFA, can be metabolized to longer chain ?3 
PUFA, mainly eicosapentaenoic acid (EPA, C20: 5?3) and 
docosahexaenoic acid (DHA, C22:6?3), whereas LA can  
be converted into arachidonic acid (AA, C20:4?6). ALA  
is present in greens, chia, flax, perilla, mustard seeds and 
oils, walnuts, soy beans, wheat; EPA and DHA are typically 
present in wild meat and eggs, and fish (salmon, tuna, her-
ring etc.); LA is present in maize, sunflower, soy bean  
and sesame oil; ARA is typically present is modern meat  
and eggs.  
 Biochemical data show that ?3 PUFAs play an important 
role in neural structure and function. The brain and CNS 
contain high concentrations of ?3 PUFAs and several studies 
suggest a role for ?3 PUFAs in neurotransmitter synthesis, 
degradation, release, reuptake and binding [16-18]. Fatty 
acids and phospholipids are part of all biological mem-
branes. The membrane’s fluidity, of crucial importance for 
its functioning, depends on its lipid components; PUFAs 
increase membrane fluidity according to their number of 
double bonds, whereas free cholesterol (CHL) increases 
membrane viscosity so that the end result depends on the 
PUFAs/CHL desaturation index [19]. DHA deficit is associ-
ated with dysfunctions of neuronal membrane stability and 
transmission of serotonin, norepinephrine and dopamine, 
which might be related to the aetiology of mood and cogni-
tive dysfunction and depression. On the other hand, EPA is 
essential to balancing the immune function and physical 
health by reducing the proportion of arachidonic acid (AA, 
C20:4?6) in cell membrane and prostaglandin E2 (PGE2) 
synthesis. A diet based on a high proportion of PUFAs  
allows for a higher incorporation of cholesterol in cell  
membranes to balance their fluidity, which, in turn, appear to 
contribute to lower blood cholesterol levels.  
 The types of fatty acids available for the make-up of cell 
membranes depend upon their relative presence in the diet. 
The retina and brain, in particularly the cerebral cortex, are 
rich in ?3 PUFAs [3, 20], and the role of ?3 in visual and 
cognitive development has been described [21-24]. Any die-
tary deficiency in ?3 PUFAs has consequences for cerebral 
development, modifying the activity of enzymes imbedded 
in cerebral membranes. In addition, it has been reported that 
maternal intake of ?3 PUFAs during pregnancy and lactation 
may have a favourable effect on the later mental develop-
ment of children [24, 25].  
 The critical factor in fatty acids' efficacy does not seem 
to be their absolute dietary intakes, but rather the ratio be-
tween their various types (C18, 20, 22-?6/3). It is known 
that the relative amounts of ?6 and ?3 PUFAs in cell mem-
branes guide their function [26, 27]. PUFAs are precursors 
of prostaglandins and leukotrienes, which are involved in 
inflammation and immune response. A diet rich in fish oil 
(?3 PUFAs) reduces production of inflammatory cytokines 
PGE2, helps in the treatment of chronic inflammatory dis-
eases such as rheumatoid arthritis and prevents the onset of 
hormone-dependent tumours (i.e. prostatic cancer) by an-
tagonizing the formation of cancerogenic factors [28]. 
 In conclusion, ?3 PUFAs play a crucial role in numerous 
cellular functions, including membrane fluidity, membrane 
enzyme activities and eicosanoid synthesis; in such respect 
they are essential for brain development in infants and also 
required for maintaining normal brain function [29]. Early 
reports suggested that large amounts of ?3 PUFAs could 
cause prolonged bleeding times, possibly resulting in hemor-
rhagic stroke, and oxidative damage to various tissues [30]. 
For this reason it is often suggested to accompany ?3 PU-
FAs supplementation with various antioxidants such as  
vitamins E, A and C, flavonoids, polyphenols etc. In fact, 
Table 1. Nutrients Having Possible Effects on Brain and  
Psychological Function 
Beneficial Effects Adverse Effects 
Omega 3 fatty acids 
Monounsaturated fatty acids 
Vegetable proteins 
Soluble fiber 
Vitamins; A,E,C, beta-carotines 
B vitamins and folic acid 
Coenzyme Q10 
Flavonoids 
Potassium 
Magnesium 
Calcium 
Zinc 
Copper 
Selenium 
Chromium 
 
Excess of Total fat 
Excess of Saturated fat 
Trans fat 
Excess of Linoleic acid 
Excess of Sodium 
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many pieces of evidence indicate that antioxidants are also 
essential for maintaining a healthy neurophysiology. 
NUTRIENTS AND AFFECTIVE FUNCTION 
 Omega-3 long chain polyunsaturated fatty acids appear 
beneficial in the treatment of several human conditions and 
diseases, including depression, schizophrenia and dementia. . 
Omega-3 treatment of these diseases often shows positive 
effects [31-35]. Discussion of its effects on depression, al-
though it might be considered controversial, has led to the 
conclusion that ?3 PUFAs can affect both affective and cog-
nitive function, and may even act as a “mood stabilizer” 
[34]. 
 Over the last decades since the 1940s, the age of onset of 
major depression in the western world has declined, and its 
incidence, on the whole, has increased up to twenty-fold. 
According to the World Health Organisation, depression is 
one of the most important diseases in the world, a fact re-
flected in the huge increase in the prescription of anti-
depressive drugs in the western world, now about three times 
as many as just two decades ago. Clinical manifestations of 
depression are fatigue, loss of vigour, anger, hostility, confu-
sion, and anxiety. WHO data indicate that the prevalence of 
depression in modern societies is relatively high – about 5-
10%. Among the ten most important disorders in developed 
countries ranked according to the “years lived with disabil-
ity” index (YLD), major depressive disorder termed 'unipolar 
major depression', clearly turned out to be ahead of all oth-
ers. In addition, 'bipolar disorder', a condition in which peri-
ods of depression alternate with periods of mania, ranks sixth 
on the list. To put that into perspective, diabetes was tenth. 
In terms of “years lost due to premature death” (YLPD), 
'unipolar major depression' ranked second only to cardiovas-
cular diseases (CVD). In a further analysis, WHO predicted a 
clear-cut increase in the relative prominence of depression 
over the next 20 years. Depression is the most frequent psy-
chiatric disorder and it affects well-being in a more funda-
mental way than other disorders. It is a life-threatening dis-
order, as about 15% of people with severe depression com-
mit suicide. 
 Several lines of evidence suggest that there is a relation 
in humans between dietary intake of ?3 PUFAs and de-
pressed mood. There is epidemiologic evidence that ?3 PU-
FAs play a role in affective function. Numerous studies have 
shown a clear link between the drop in ?3 PUFAs consump-
tion (i.e. fish) and the risk of depression, particularly as the 
incidence of this disorder varies, depending on the country, 
parallel with fish consumption. In this regard, numerous 
negative correlations have been demonstrated between 
worldwide fish consumption and rates of depression. One of 
the most famous and the most spectacular studies in this area 
was conducted by Joseph R. Hibbeln [35]. They showed a 
strong negative association (r=-0,84) between fish intake and 
depression across 13 countries (among 35000 citizens). Sil-
vers and Scott [36] found that the personal perception of 
good mental and physical health varies with the consumption 
of fish (rich in ?3 PUFAs) in New Zealand. Timonen et al. 
[37] showed an increased risk of developing depression in 
persons who rarely ate fish compared with regular fish eat-
ers. Other analysis [38] reported a connection between die-
tary seafood intake and protection against bipolar disorder 
and against seasonal affective disorder [39]. Similar results 
have been reported by Parker et al. [40]. 
 Here, it is worthwhile to emphasize that the studies cited 
above are cross-sectional and that significant correlations 
may always reflect associations with other uncontrolled fac-
tors (i.e. smoking). 
 A relationship between ?3 intake and depressed mood 
has also been found in clinical studies. However, only a few 
studies have focused on dietary factors, a fact which shows 
their underestimated recognition in research on depression. 
Lower concentrations of ?3 have been reported in the 
plasma/red blood cell membranes of persons with major de-
pressive disorder diagnosis compared with matched non-
depressed control subjects [41-43]. Tiemeier et al. [44] 
found in a group of 567 participants statistically significant 
lower ?3 PUFAs levels, and higher ?6/?3 ratios in blood 
serum in individuals with depressive disorder than in the 
non-depressed control group. Stoll et al. [34] observed im-
provements in the depressive symptoms associated with bi-
polar disorder after supplementation with ?3 PUFAs com-
pared with placebo, and Nemets et al. [45] reported benefits 
of ?3 PUFAs compared with placebo for treating unipolar 
disorder.  
 The role of ?3 PUFAs in major depressive disorder has 
been studied by Su et al. [69]. They conducted an 8-week 
double-blind, placebo controlled trial comparing ?3 PUFAs 
(9,6g/d) with placebo, on top of the usual treatment. Interest-
ingly, participants in the ?3 PUFAs group had significant 
differences in HRSD (Hamilton Rating Scale for Depres-
sion) score from the fourth week after treatment (and this 
difference kept growing up to week 8) – though it was a pre-
liminary trial and small sample. 
 Tanskanen et al. [46, 47] in research on a random sam-
ple, found that frequent fish consumption might be coupled 
with a reduced risk of suicidal ideation. In the Huan et al. 
study [48] there was nearly eightfold difference in the num-
ber of suicide attempts between the lowest and highest red 
blood cells EPA level quartiles. 
 Very interesting results on ?3 PUFAs effects on mood, 
cognitive and physiological function have been reported by 
researchers from the University of Siena [49]. The study 
aimed to examine the effects of ?3 supplementation on 
healthy volunteers performing a series of attention tests (tests 
involving different types of attention were used). The tests 
were accompanied by neurophysiological recordings (elec-
troencephalogram «EEG» and electromyography «EMG») to 
evaluate the possible modification of neuroelectrical parame-
ters. In each test the participants’ mood was diagnosed (in-
volving The Profile of Mood States «POMS») and the reac-
tion time was recorded. Subjects were tested at the beginning 
of the experiment and after thirty five days. Blood samples 
were taken on day 1 and day 35 to analyze specific parame-
ters: AA/EPA ratio, cholesterol, triglycerides, High-density 
lipoprotein (HDL), Low-density lipoprotein (LDL) and gly-
caemia. Over a period of 35 days they were supplemented 
with ?3 PUFAs. A control group was supplemented with 
placebo (olive oil). After 35-day supplementation, blood 
analyses showed that the AA/EPA ratio was strongly re-
duced by ?3 treatment. Supplementation with ?3 PUFAs 
was associated with clear variations in mood. The POMS 
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analysis showed an increase in vigour and decrease in such 
mood states as: anger, anxiety, fatigue, depression and con-
fusion. The reaction time in attention tests decreased after 
?3. An EEG frequency distribution showed a shift towards 
low frequencies in all recordings after ?3 supplementation. 
In particular, after ?3 the percentage of the beta-2 band de-
creased significantly in all tests and in the relaxation period. 
Its reduction was accompanied by a concomitant increase of 
the theta and alpha bands. Though it was a relatively small 
sample, the results strongly suggest that ?3 PUFA supple-
mentation has a beneficial influence on general psychologi-
cal state, including mood and cognitive function, non-
specific for depressive disorders. Data supplied by Fontani et 
al. reinforce the hypothesis of the direct action of ?3 fatty 
acids on the central nervous system. The authors assume that 
the importance of these results is strengthened by the fact 
that they occur within subjects in good health and leading a 
physically active life in whom ?3 PUFAs improved an al-
ready good condition of well-being. 
 Omega-3 PUFA supplementation is reported to be bene-
ficial in psychological distress [50]. Based on the evidence 
from epidemiological data, case-control studies of phosphol-
ipid PUFA levels in human tissues, and antidepressant effect 
in clinical trials, it can be concluded that ?3 PUFAs could 
help to decipher the unsolved enigma of depression and con-
nect the body and mind. The deficit of ?3 PUFAs has been 
reported to be associated with neurological, autoimmune, 
cardiovascular, cerebrovascular and metabolic diseases, can-
cers, and psychological conditions and diseases. Animals fed 
with high ARA diet or treated with PGE2 were observed to 
show symptoms of low activity, anorexia, change in sleep 
pattern and attention, which are similar to somatic symptoms 
of depression in humans. The deficit of EPA and DHA in 
depression may be linked with cognitive dysfunction, mood 
disturbance, medical co-morbidity and somatic symptoms in 
depression. The role of ?3 PUFAs in immunity and mood 
function supports the promising psycho-neuro-immunolo- 
gical hypothesis of depression and provides an excellent ex-
ample of body and mind interface [11]. 
 It has not been precisely determined how ?3 PUFAs af-
fect psychological function. There are several possible 
mechanisms by which EPA and DHA could improve mood 
in affective disorders. EPA and DHA are intrinsic to the mo-
lecular structure of the phospholipids of cell membranes. 
The fatty acids are crucial to their role in modulating the 
functioning of proteins in the membrane. PUFAs lend fluid-
ity to cell membranes and have specific functional interac-
tions with membrane enzymes, receptors and other proteins. 
EPA and DHA can inhibit protein kinase C signal transduc-
tion enzyme complex, block calcium influx into the cell 
through the L-type calcium channel, similar to the calcium 
channel blockers verapamil or nimodipine [31]. Omega-3 
fatty acids are often employed in conjunction with conven-
tional medicine. That is because some psychiatric patients 
with depression or persistent anxiety are dissatisfied with the 
apparent ineffectiveness of traditional treatments and seek a 
more holistic approach with fewer side effects. The role of 
?3 PUFAs as an adjunct to antipsychotics and melatonin as a 
treatment or prophylactic agent for side effects remains am-
biguous, requiring further trials with sound methodology 
[51]. 
 In order to compile and compare data from different tri-
als, Appleton et al. [52, 53] conducted a study which aimed 
to systematically review several published randomized con-
trolled trials investigating the effects of ?3 PUFAs on de-
pressed mood. 
 Eight medical and health databases were thoroughly 
searched for all years on record up to June 2006 for trials 
that exposed participants to ?3 PUFAs or fish, measured 
depressed mood, and were conducted on human participants 
with inclusion of a reference group.  
 Twelve randomized controlled trials were identified and 
included in the meta-analysis. The participants either had 
diagnosis of various different clinical conditions or were 
healthy volunteers. The pooled standardized difference in 
mean outcome (fixed-effect model) was 0.13 SDs (95% CI: 
0.01; 0.25) in those receiving ?3 PUFAs compared with 
placebo, with strong evidence of heterogeneity. A sensitivity 
analysis that excluded one large trial increased the effect size 
but did not reduce heterogeneity. Meta-regression provided 
some evidence that the effect was stronger in trials involving 
populations with major depression – the difference in the 
effect size was 0.73 (95% CI: 0.05; 1.41; P=0.04), but there 
was still significant heterogeneity when trials that involved 
populations with major depression were pooled separately. 
 Appleton and associates’ research indicates that trial evi-
dence which examines the effects of ?3 PUFAs on depressed 
mood is limited and difficult to summarize and evaluate, due 
to its considerable heterogeneity. Most trials were small in 
scale, short in duration, and used different combinations of 
different doses of ?3 in varied groups of subjects. The evi-
dence analyzed provides some support for the use of ?3 PU-
FAs in improving depressed mood. Larger trials with ade-
quate precision to detect clinically important benefits are still 
required. 
 Indeed, the effects of ?3 PUFAs on depressed mood and 
cognitive function remain unclear. In fact, there is a number 
of studies showing the lack of therapeutically important ef-
fects of ?3 PUFA supplementation on mood and psycho-
logical states.  
 Silvers et al. [54] conducted a placebo-controlled trial of 
fish oil in the treatment of depression. They found no evi-
dence that fish oil improved mood when compared to pla-
cebo oil. A study by Hakkarainen et al. [55] examined a total 
of 29.133 men aging from 50 to 69 years in a population-
based trial in Finland and did not find associations between 
the dietary intake of ?3 PUFAs or fish consumption and 
depressed mood, major depressive episodes or suicide. How-
ever, we must take under consideration that mean fish con-
sumption is much higher in Finland then in many other 
European countries (i.e. Poland). British researchers [56] 
conducted a large double-blind randomised controlled trial to 
evaluate the effects of EPA+DHA supplementation (1,5 g/d) 
on mood and cognitive function in mildly to moderately de-
pressed individuals (190 participants completed 12 weeks 
intervention). Compliance, confirmed by plasma fatty acid 
concentrations, was good, but there was no evidence of a 
difference between supplemented and placebo groups in the 
depression subscale of DASS (Depression, Anxiety and Stress 
Scales) at 12 weeks (adjusted differentce in mean: -1,0; 95% 
56    The Open Nutraceuticals Journal, 2011, Volume 4 Wilczynska et al. 
CI; P=0,27). Other measures of mood, mental health and 
cognitive function, including Beck Depression Inventory 
(BDI) score and attention bias toward threat words, were 
similarly little affected by the intervention. Substantially 
increasing EPA+DHA intake for 3 months was found not to 
have beneficial or harmful effects on mood in mild to mod-
erate depression 
 Table 2 presents the findings of available articles. It in-
cludes: authors, year of publication, type and size of research 
group, daily dose applied in research and obtained results 
[see 57-84]. The table shows different effects of ?3 on de-
pressed mood. 
NUTRIENTS AND COGNITIVE FUNCTION 
 It seems ?3 PUFA intake may be associated with human 
cognitive function. However, the majority of studies con-
ducted in this field have considered only pathological situa-
tions. Many investigations have ascertained that dietary in-
take of fish and ?3 PUFAs is associated with lower risk of 
cognitive impairment, Alzheimer disease, dementia and 
stroke [i.e. 32, 84-89]. Relatively few studies have examined 
the beneficial role of ?3 PUFAs on cognitive performance in 
healthy adults. 
 Assessments of the cognitive benefits in adults are lim-
ited because of a lack of information on the characteristics 
and diets of food supplement users and the fact that those 
who seem healthier are also more likely to watch their diet, 
use supplements, etc. The relationship between better reten-
tion of cognitive function in later life and diet might be ex-
plained by better lifelong cognitive function informing 
health choices in old age. 
 The studies in this field also use observational design and 
relatively few studies of the cognitive benefits of proper diet 
and food supplement use have adjusted the results for the 
possible role of mental ability in earlier life, mainly because 
this information is usually not available. There is strong sug-
gestion that ?3 PUFA intake affects cognitive performance 
in adults.  
 Whalley et al. [90, 91] conducted an observational study 
of 350 mentally efficient subjects born in 1936 whose mental 
ability was tested in 1947 and who were followed up to in 
2000/01, at which point cognition, supplement use, diet, and 
risk factors for vascular disease were assessed. This investi-
gation showed that use of food supplements in late adulthood 
can influence cognitive performance. This influence does not 
depend on differences in cognitive ability present in child-
hood. Specific cognitive advantages at the age of 64 were 
found in users of food supplements, including fish oils - 
compared with non-users. Cognitive advantages were found 
in the digit symbol subtest, which is highly sensitive to cog-
nitive aging and Alzheimer disease. The blood samples of 
fish oil users and nonusers were examined; there were sig-
nificant correlations between childhood IQ and erythrocyte 
?3 PUFAs in 2000/01. This means that higher childhood IQ 
is probably related to higher ?3 PUFA / fish oil consumption 
in later adulthood. IQ at age 64 y was significantly correlated 
in the total sample with erythrocyte ?3 PUFA content and 
with the ratios of DHA/AA and ?6/?3 PUFAs. Whalley et 
al. conclude that greater dietary fish oil consumption is re-
lated to higher cognitive function in late adulthood. 
 The results coincide with those of the investigation con-
ducted by Nurk et al. [92]. A large cross-sectional study with 
2031 healthy subjects over 70 y showed a similar relation 
between intake of different amounts of seafood and cognitive 
performance.  
 It was found that fish eaters have significantly better re-
sults on all six cognitive tests used (Kendrick Object Learn-
ing Test «KOLT», Trial Making Test Part A «TMT-A», 
Digit Symbol Test Modified «m-DST», Block Design «m-
BD», Modified version of the Mini-Mental State Examina-
tion «m-MMSE», Abridged version of the Controlled Oral 
Word Association «S-task») than non-consumers. People 
who declared mean daily intake of fish and fish products 
?10g/d had significantly better mean results in cognitive 
tests and a lower prevalence of poor cognitive performance 
than did those whose intake was <10g/d. The associations 
between total intake of seafood and cognition strongly de-
pended on dose and the type of fish. The maximum effect 
was reported at an intake of about 75g/d and with fatty fish 
(a richest source of ?3 PUFAs). 
 The association between plasma ?3 PUFA proportions 
and cognitive performance in older adults was also shown in 
another longitudinal study [93]. Researchers found that 
higher plasma proportions of ?3 PUFA predicted signifi-
cantly less decline in such cognitive domains as sensory mo-
tor speed and complex speed over three years than did lower 
proportions of ?3 PUFAs. 
 It has not been determined whether cognitive decline is 
pathological or the result of a normal aging process. None-
theless, current scientific data indicates that fish / ?3 PUFA 
consumption may be associated with slower decline; which 
seems a valuable piece of information. 
 The results above ought to be considered with a dose of 
scepticism. As in all observational studies, the direction of 
associations between cognitive scores in late life, self-
reported supplement use, and blood ?3 PUFAs, remains un-
certain. In example, participants with higher mental ability 
may be better informed about healthy nutritional habits, and 
eat a diet rich in ?3, vitamins etc. 
 Randomized controlled trials offer much greater degree 
of control of experimental variables, such as composition 
and quantity of taken PUFAs, than do observational studies. 
Such design allows us to avoid many of the potential prob-
lems that often render more difficult the interpretation of 
observational study. 
 The effects of ?3 supplementation on some cognitive and 
physiological parameters in healthy subjects (22 to 51 y) 
have been examined in controlled trials conducted by Fon-
tani et al. [49]. Different types of attention have been meas-
ured in a 35-day ?3 PUFA supplementation group vs pla-
cebo group. Omega-3 PUFA supplementation has been 
found to be associated with a positive effect on reactivity, 
i.e. reduction of reaction time in the Go/No-Go and Sus-
tained Attention tests. The latency of EMG activation was 
concomitantly reduced in the same test plus Choice. EEG 
frequency shift to the alpha and theta band were recorded in 
all the tests after ?3 PUFA supplementation. These results 
indicate a beneficial influence of ?3 PUFAs on cognitive 
functions (attention) in healthy humans. It is possible that 
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Table 2. Chronological List of Clinical Trials Investigating Effects of Omega-3 PUFA on Depressed Mood and other Affective 
Manifestations 
Daily dose Duration (d)
1 Behan et al. 1990 chronic fatigue syndrome 63: 39/24
0,14g EPA
0,09g DHA
90 Likert scale Yes
2 Warren et al. 1999 chronic fatigue syndrome 50: 24/26
0,14g EPA
0,09g DHA
90 BDI No
3 Stoll et al. 1999 bipolar disorder 30: 14/16
6,2g EPA
3,4G DHA
112
HDRS
YMRS
CGI
GAS
Yes
4 Keck et al. 2002 bipolar disorder 116: 59/57 6,0g E-EPA 120
IDS
YMRS
No
5 Nemets et al. 2002 unipolar depressive disorder 20: 10/10 2,0g E-EPA 28 HDRS Yes
6 Peet and Horrobin 2002 major depression
70: 17 _ 1g/d
18_ 2g/d
17_ 4g/d 
1;2;4g EPA 84
HDRS
MADRS
BDI
Yes
7 Llorente et al. 2003 postpartum depression 99: 44/45 ok. 0,2g DHA 120 BDI No
8 Marangell et al. 2003 major depression 36: 18/18 2,0g DHA 42
MADRS
HDRS
No
9 Su et al. 2003 major depression 28: 14/14
4,4g EPA
2,2g DHA
56 HDRS Yes
10
Zanarini and 
Frankenburg
2003 borderline personality disorder 30: 20/10 1,0g E-EPA 56
MADRS
MOAS
Yes
11 Post et al. 2003 bipolar disorder 121 6g EPA 112 - No
12 Fux et al. 2004 obsessive compulsive disorder 11 2,0g E-EPA 42
HDRS
YBOCS
No
13 Hirashima et al. 2004 bipolar disorder 21: 12/9
5,0-5,2g EPA
3,0-3,4 DHA 
or
1,3g EPA
0,7g DHA
28
T2 time
HDRS
Yes
14 Silvers et al. 2005 major depression 77: 40/37
0,6g EPA
2,4 g DHA
84
HDRS-SF
BDI
No
15 Fontani et al. 2005 healthy subjects 49: 33/16
1,6g EPA
0,8g DHA
0,4g other n-3 PUFAs
35 POMS Yes
16 Osher et al. 2005 bipolar disorder 12 1,5-2g EPA up to 168 HDRS Yes
17 Freeman et al. 2005 postpartum depression
16: 
6_ 0,5g EPA+DHA
3_ 1,4g EPA+DHA
7_ 2,8g EPA+DHA
0,5g EPA+DHA
1,4g EPA+DHA
2,8g EPA+DHA
ratio EPA:DHA_ 1,5:1
56
EPDS
CGI
HRSD
(lack of 
placebo-
control group)
18 Frangou et al. 2006 bipolar disorder
75: 24_ 1g/d
25_  2g/d
26_ placebo
1;2g/d E-EPA 84
HDRS
CGI
YMRS
Yes
19 Nemets et al. 2006 (children) [6-12y] major depression 28: 13/15
0,38-0,4g EPA
0,18-0,2g DHA
112
CDRS
CDI
CGI
Yes
20 Hallahan et al. 2007 patients with recurrent self-harm 49: 22/27 1,2g EPA + 0,9g DHA 84
BDI
HDRS
MOAS 
IMT/DMT
PSS
Yes
21 Rogers et al. 2008 mild to moderate depressive disorder 190: 96/94
0,63g EPA
0,85g DHA
84
DASS
BDI
GHQ
STAI
No
22 van de Rest et al. 2008
older subjects (?65 y) independently 
living
302
1,8g EPA+DHA
or
0,4g EPA+DHA
182
CES-D
MADRS
GDS-15
HADS-A
No
23
Buydens-
Branchey et al.
2008 substance abusers 22: 11/11
2,25g EPA + 0,5g DHA + 
0,25 other PUFAs
84 POMS Yes
middle aged women with moderate-to-
severe psychological distress 
(with and without MDE diagnosis)
120: 59/61
1,05g E-EPA
0,15g E-DHA
56
PGWB
HSCL-D-20
HDRS
No
middle aged women with moderate-to-
severe psychological distress
(without MDE diagnosis)
91: 46/45
1,05g E-EPA
0,15g E-DHA
56
PGWB
HSCL-D-20
HDRS
Yes
Statistical 
significant 
difference 
24 Lucas et al. 2009
No. Study Year Group
No. of subjects, total: 
treatment/placebo
Intervention
Outcome 
measures
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they improve an already healthy level of cognitive function. 
The authors definitely ascribe changes in the reaction time 
and psychological parameters to the action of ?3 on the cen-
tral nervous system. These results are in line with the above 
mentioned effects of ?3 PUFAs in pathological circum-
stances. 
 In a double-blind, randomized and placebo-controlled 
study involving 30 young women, results indicate that sup-
plementation with zinc may be effective in reducing anger 
and depression (94). The women were randomized to one of 
two groups for a period of 10 weeks: 1) zinc group: (n=15) 
received multivitamins + zinc (7 mg/day); control group: 
(n=15) received multivitamins daily. Women in the zinc 
group showed significant reduction in anger-hostility score 
and depression-dejection score (P=0.011) in the Profile of 
Moods State (POMS). Thus, the authors of this study con-
clude, "Our results suggest that Zn supplementation may be 
effective in reducing anger and depression"[94]. 
CONCLUSIONS 
 In this work we have outlined the evidence that particular 
nutrients influence the structure, the biochemistry and the 
functioning of the central nervous system. Fatty acids of the 
?3 family probably have a beneficial effect on both affective 
and cognitive function, probably more in long term preven-
tion and in acute treatment. Although some lines of investi-
gation showed negative results, the data available shed new 
light on potential nutrition issues relative to the modern diet, 
and open the field to further studies. 
 The data concerning ?3 PUFAs effects on affective and 
cognitive function remain rather limited and often ambigu-
ous in interpretation. However, the available evidence forces 
us to lend thorough consideration to the issue of dietary 
management in treating depression and other mental disor-
ders. These data provide topics for interpretation and further 
research, which seems crucial. Indeed, the role of ?3 PUFAs 
in affecting immunity and affective function may support the 
promising psycho-neuro-immunological hypothesis of de-
pression and appears to reveal the interface of body and 
mind (holistic approach). It seems that polyunsaturated fatty 
acids may become useful for prophylactic and/or therapeutic 
treatment of mood disorders and even for cognitive decline 
in senescence. What is more, it has been suggested that ?3 
PUFAs might play a similarly beneficial role also in healthy 
humans’ mental function. Data indicate that high ?3 PUFA 
dietary consumption might stabilize one’s mood by reducing 
negative emotional states such as anxiety, anger and depres-
sion. The nutrients are considered to be factors that induce 
rather short term effects, so that they should be administrated 
on a continuing basis to maintain long term efficacy. 
 More studies, however, are needed, particularly with 
double-blind placebo controlled trials. Although functional 
effects on the CNS of dietary variations in essential fatty 
acids seem widely accepted as a fact, the underlying bio-
chemical mechanisms are poorly understood and are not cur-
rently an area of intensive study. As noted, a great deal of 
studies on correlates between psychological outcomes and 
dietary compounds mainly involve pathological situations. 
Data concerning nutrients and affective/cognitive function of 
healthy people remain insufficient. One might have reserva-
tions about the dietary-intake-control methods typically used 
– such as dietary questionnaires, ?3 PUFA blood level 
(which does not say much about past nutrition habits), and 
about fish consumption recommendations and/or supplement 
capsules intake in intervention trials. Moreover, the most 
controlled trials published have been rather small and the 
duration rarely exceeded 90 days. It seems essential to pro-
vide randomised trials with functional food enriched in pre-
cisely determined specific nutrients composition. 
 There are still further unsolved issues related to the role 
of ?3 fatty acids. First of all, there is not enough data on 
potential undesirable effects of long term ?3 supplementa-
tion. Why does the 1- 2 g/d ?3 PUFA dose seem more effec-
tive than higher amounts? What is the optimal ratio between 
EPA and DHA? And finally, what period of regular supple-
mentation is necessary in order to reach maximal therapeutic 
response? [95, 96] 
 We believe that the significance of ?3 PUFAs in diet is 
undeniable, as they have been a natural part of our diet since 
the onset of the brain across all living species, humans in 
particular. In fact, it is only in the last two centuries that con-
sumption of ?3 PUFAs has decreased in the western world, 
mainly because of food processing and commercial issues. 
Many authors see this dietary change as one of the main 
sources of continual increase in chronic degenerative dis-
eases in modern societies. It appears that ?3 polyunsaturated 
fatty acids may become useful in both prophylaxis and 
treatment of many human conditions including mental disor-
ders. It seems vital to gradually fill the gaps in common 
knowledge in this area. 
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